Antonio Mastroianni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Antonio Mastroianni has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
- Sonia Greco
Infectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
19 shared publications Sonia Greco
Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
16 shared publicationsValeria Vangeli
Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
16 shared publications- Valeria Vangeli
Infectious & Tropical Diseases Unit, “Annunziata” Hub Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy
15 shared publications - Maria Vittoria Mauro
Microbiology Unit, “Annunziata” Hub Hospital, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy
14 shared publications Francesca Greco
Microbiology Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza, Italy
9 shared publications
Latest Publications
- 27 October 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 22, 1-7
Safety and Efficacy of Combination Antibiotics and Systemic Immunotherapy as Salvage Therapy for Severe Deep Neck Abscess: A Retrospective Case Series with Observational Analysis
Introduction/Objective: Deep Neck Abscess (DNA) is a rapidly progressive softtissue infection with high morbidity and mortality rates, especially in the elderly. The natural course involves the soft tissues of the neck with erosion of major blood vessels. The objective of this monocenter, retrospective case series study with observational analysis was to evaluate the safety and efficacy of low-dose Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in combination with intravenous antibiotics to improve clinical outcomes and reduce mortality in patients with severe DNAs and sepsis. Methods: Seven immunocompetent patients with confirmed bacterial sepsis and DNAs were evaluated over an 8-year period. Diagnosis was established via Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and positive cultures. Patients received combination therapy consisting of customized intravenous antibiotics and subcutaneous GM-CSF (10 mcg/kg daily) for 5–7 days, alongside aggressive surgical debridement and supportive care. This study adhered to the CARE guidelines for case series and STROBE guidelines for observational analysis. Results: The addition of GM-CSF to intravenous antibiotics and surgical care was safe and well tolerated. All seven patients achieved full clinical recovery with a 100% survival rate through day 29. No local or systemic complications, subsequent organ dysfunction, or thoracic extension of the infection were reported. Discussion: GM-CSF acts as a potent hematopoietic growth factor that stimulates myeloid lineage proliferation and enhances macrophage phagocytosis and neutrophil microbicidal activity. Its adjunctive use provides a synergistic survival benefit and emergency myelopoiesis to accelerate pathogen clearance in non-neutropenic severe tissue infections. Conclusion: Combining targeted antimicrobial coverage with adjunctive low-dose GM-CSF immunotherapy offers a promising, safe, and effective salvage strategy for severe deep neck abscesses, associated with low complication rates and excellent survival outcomes.
- 27 October 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 22, 1-7
Safety and Efficacy of Combination Antibiotics and Systemic Immunotherapy as Salvage Therapy for Severe Deep Neck Abscess: A Retrospective Case Series with Observational Analysis
Introduction/Objective: Deep Neck Abscess (DNA) is a rapidly progressive softtissue infection with high morbidity and mortality rates, especially in the elderly. The natural course involves the soft tissues of the neck with erosion of major blood vessels. The objective of this monocenter, retrospective case series study with observational analysis was to evaluate the safety and efficacy of low-dose Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in combination with intravenous antibiotics to improve clinical outcomes and reduce mortality in patients with severe DNAs and sepsis. Methods: Seven immunocompetent patients with confirmed bacterial sepsis and DNAs were evaluated over an 8-year period. Diagnosis was established via Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and positive cultures. Patients received combination therapy consisting of customized intravenous antibiotics and subcutaneous GM-CSF (10 mcg/kg daily) for 5–7 days, alongside aggressive surgical debridement and supportive care. This study adhered to the CARE guidelines for case series and STROBE guidelines for observational analysis. Results: The addition of GM-CSF to intravenous antibiotics and surgical care was safe and well tolerated. All seven patients achieved full clinical recovery with a 100% survival rate through day 29. No local or systemic complications, subsequent organ dysfunction, or thoracic extension of the infection were reported. Discussion: GM-CSF acts as a potent hematopoietic growth factor that stimulates myeloid lineage proliferation and enhances macrophage phagocytosis and neutrophil microbicidal activity. Its adjunctive use provides a synergistic survival benefit and emergency myelopoiesis to accelerate pathogen clearance in non-neutropenic severe tissue infections. Conclusion: Combining targeted antimicrobial coverage with adjunctive low-dose GM-CSF immunotherapy offers a promising, safe, and effective salvage strategy for severe deep neck abscesses, associated with low complication rates and excellent survival outcomes.
- Open Access
- 8 October 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (12)
Burkholderia cepacia complex prosthetic aortic valve endocarditis
- 8 October 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (12)
Open AccessBurkholderia cepacia complex prosthetic aortic valve endocarditis
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-6
Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19
Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made regarding drugs to use in patients with Refractory Cytokine Release Syndrome (CRS) after the use of first-line anticytokine drugs. The objective of this report was to evaluate the efficacy of sequential immunomodulatory therapies in the management of refractory CRS in COVID-19 patients. Methods: From March 2020 to March 2023, 1,025 patients with COVID-19 were admitted to the Infectious and Tropical Diseases ward at the Annunziata Cosenza Hub Hospital in Cosenza, Italy. To determine how many patients with refractory COVID-19-associated CRS were treated with combinedsequential therapy involving tocilizumab, a recombinant humanized anti-Interleukin-6 (IL-6) receptor monoclonal antibody, and baricitinib, a Janus kinase inhibitor, or anakinra, a recombinant human interleukin- 1 receptor antagonist, the electronic medical records of all hospitalized patients with COVID-19 were reviewed. The primary outcome was the incidence of CRS by day 29. Secondary outcomes included in-hospital mortality and 30-day mortality, to assess hospital performance and patient safety. Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched through June 30, 2026, for case-series and studies evaluating the efficacy of sequential combined immunomodulatory systemic therapies in the management of refractory CRS in critically ill patients with COVID-19. Results: From January 2021 to December 2023, a total of 25 patients received sequential combined immunomodulatory systemic therapies, including tocilizumab and baricitinib or anakinra, in the management of COVID-19-related CRS. After 72 hours from the introduction of the new anti-cytokine therapy, a significant improvement of respiratory parameters, clinical state, inflammatory markers, and blood counts was observed. All patients survived, and those 5 previously mechanically ventilated patients were extubated. Non-infectious or infectious pulmonary or systemic complications were observed in all patients who underwent sequential combined immunomodulatory systemic therapies. Discussion: The study’s findings suggest that tocilizumab used in sequential combination with baricitinib or anakinra, in conjunction with standard of care treatments, was associated with improved outcomes in critically ill patients with COVID-19 disease and early discharge from the hospital. Conclusion: There is clear rationale for using combined immunomodulatory systemic therapies in critically ill patients who develop refractory CRS. The results of the experience, supported by a review of the current literature, suggest the need for larger-scale studies on sequential and combined systemic immunomodulatory therapies to manage refractory CRS in critically ill patients with COVID-19.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-6
Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19
Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made regarding drugs to use in patients with Refractory Cytokine Release Syndrome (CRS) after the use of first-line anticytokine drugs. The objective of this report was to evaluate the efficacy of sequential immunomodulatory therapies in the management of refractory CRS in COVID-19 patients. Methods: From March 2020 to March 2023, 1,025 patients with COVID-19 were admitted to the Infectious and Tropical Diseases ward at the Annunziata Cosenza Hub Hospital in Cosenza, Italy. To determine how many patients with refractory COVID-19-associated CRS were treated with combinedsequential therapy involving tocilizumab, a recombinant humanized anti-Interleukin-6 (IL-6) receptor monoclonal antibody, and baricitinib, a Janus kinase inhibitor, or anakinra, a recombinant human interleukin- 1 receptor antagonist, the electronic medical records of all hospitalized patients with COVID-19 were reviewed. The primary outcome was the incidence of CRS by day 29. Secondary outcomes included in-hospital mortality and 30-day mortality, to assess hospital performance and patient safety. Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched through June 30, 2026, for case-series and studies evaluating the efficacy of sequential combined immunomodulatory systemic therapies in the management of refractory CRS in critically ill patients with COVID-19. Results: From January 2021 to December 2023, a total of 25 patients received sequential combined immunomodulatory systemic therapies, including tocilizumab and baricitinib or anakinra, in the management of COVID-19-related CRS. After 72 hours from the introduction of the new anti-cytokine therapy, a significant improvement of respiratory parameters, clinical state, inflammatory markers, and blood counts was observed. All patients survived, and those 5 previously mechanically ventilated patients were extubated. Non-infectious or infectious pulmonary or systemic complications were observed in all patients who underwent sequential combined immunomodulatory systemic therapies. Discussion: The study’s findings suggest that tocilizumab used in sequential combination with baricitinib or anakinra, in conjunction with standard of care treatments, was associated with improved outcomes in critically ill patients with COVID-19 disease and early discharge from the hospital. Conclusion: There is clear rationale for using combined immunomodulatory systemic therapies in critically ill patients who develop refractory CRS. The results of the experience, supported by a review of the current literature, suggest the need for larger-scale studies on sequential and combined systemic immunomodulatory therapies to manage refractory CRS in critically ill patients with COVID-19.
- Open Access
- 21 September 2026
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 39 (5) , 468
Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease
- 21 September 2026
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 39 (5) , 468
Open AccessEfficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease
- Open Access
- 29 July 2026
- Published by Wolters Kluwer Health in Asian Pacific Journal of Tropical Medicine
- Vol. 19 (8) , 371-373
Unexpected schistosomiasis presenting as acute appendicitis in a migrant adult
Was not provided for this article.
- 29 July 2026
- Published by Wolters Kluwer Health in Asian Pacific Journal of Tropical Medicine
- Vol. 19 (8) , 371-373
Open AccessUnexpected schistosomiasis presenting as acute appendicitis in a migrant adult
Was not provided for this article.
- Open Access
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Open AccessImproving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- Open Access
- 25 May 2026
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 22 (3)
SARS-CoV-2 as a cause of fatal intestinal perforation
Gastrointestinal (GI) perforation in association with COVID-19 is uncommonly reported in the literature. In this study, our goal was to elucidate the possible pathologic role of SARS-CoV-2 on the GI tract in a patient suffering from intestinal perforation. A literature review using PubMed identified 40 additional cases of COVID-19-related GI perforation. Including our case, a total of 41 cases has been described in the literature, 18 of which were fatal. Including our case, in only three cases SARS-CoV-2 RNA was detected in intestinal surgical specimens. The detection of Sars-Cov-2 viral RNA in GI tissue samples has not been adequately standardized, and consistent results are lacking. Regular testing for SARS-CoV-2 in biopsy and surgical specimens would be necessary to establish its true, direct pathological role in the GI manifestations associated with COVID-19, also in those patients with severe illness or on treatments like glucocorticoids and tocilizumab.
- 25 May 2026
- Published by PAGEPress Publications in Emergency Care Journal
- Vol. 22 (3)
Open AccessSARS-CoV-2 as a cause of fatal intestinal perforation
Gastrointestinal (GI) perforation in association with COVID-19 is uncommonly reported in the literature. In this study, our goal was to elucidate the possible pathologic role of SARS-CoV-2 on the GI tract in a patient suffering from intestinal perforation. A literature review using PubMed identified 40 additional cases of COVID-19-related GI perforation. Including our case, a total of 41 cases has been described in the literature, 18 of which were fatal. Including our case, in only three cases SARS-CoV-2 RNA was detected in intestinal surgical specimens. The detection of Sars-Cov-2 viral RNA in GI tissue samples has not been adequately standardized, and consistent results are lacking. Regular testing for SARS-CoV-2 in biopsy and surgical specimens would be necessary to establish its true, direct pathological role in the GI manifestations associated with COVID-19, also in those patients with severe illness or on treatments like glucocorticoids and tocilizumab.
- 19 April 2026
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 32 (3) , 14
Journal of neurovirology
- 19 April 2026
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 32 (3) , 14
Journal of neurovirology
- Open Access
- 9 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 845
New Advancements in the Field of Leishmaniasis
Leishmaniasis is the term used to characterize a spectrum of human diseases caused by more than 20 different Leishmania parasite species
- 9 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 845
Open AccessNew Advancements in the Field of Leishmaniasis
Leishmaniasis is the term used to characterize a spectrum of human diseases caused by more than 20 different Leishmania parasite species
- Open Access
- 1 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (4) , 1075-1092
Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study
Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.
- 1 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (4) , 1075-1092
Open AccessOritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study
Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.